This Plain Language Summary of publication article (PLSP) from Future Oncology covers two studies on N-803 (Anktiva) combined with bacillus Calmette-Guerin (BCG) for non-muscle invasive bladder cancer (NMIBC). The Phase 1b study tested increasing doses of N-803 with BCG in BCG-naive patients, while the Phase 2/3 study evaluated the combination in patients unresponsive to BCG alone.

Visit the site using this link to read the article.

This PLSP is based on articles called ‘Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer’ published in OncoImmunology and ‘IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer’ published in NEJM Evidence.

Visit Taylor & Francis Online using the link to read the original article on Phase 1b

Visit NEJM Evidence using the link to read the original article on Phase 2/3